Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice

Journal of Clinical Investigation

Volumn 97, Issue 5, 1996, Pages 1204-1210

  Kunzendorf, Ulrich ^a   Pohl, Thomas ^a   Bulfone Paus, Silvia ^a   Krause, Hans ^a   Notter, Michael ^a   Onu, Adrian ^a   Walz, Gerd ^b   Diamantstein, Tibor ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

cell mediated immune response; fusion proteins; immunoligands; immunosuppression

Indexed keywords

CD3 ANTIGEN; CHIMERIC PROTEIN; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CONTROLLED STUDY; CYTOLYSIS; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; FEMALE; GRAFT REJECTION; HOST RESISTANCE; HUMORAL IMMUNITY; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030003594     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118534     Document Type: Article

References (31)

1. Debure, A., N. Chkoff, L. Chatenoud, M. Lacombe, H. Campos, L.H. Noel, G. Goldstein, J.F. Bach, and H. Kreis. 1988 One-month prophylactic use of OKT3 in cadaveric kidney transplant recipients. Transplantation (Baltimore). 45:546-553.
2. Hourmant, M., F. Babinet, D. Cantarovich, M. Latour, J. Carcagne, H. Vie, M Bonneville, J.F. Moreau, E. Carosella, and J.D. Bignon. 1989. Polyclonal rabbit gamma globulins against a human cytotoxic CD4 T cell clone. II Use in prevention of rejection in kidney transplantation: a pilot study. Transplantation (Baltimore). 48:260-263.
3. Diamantstein, T., and H. Osawa. 1986. The interleukin-2 receptor, its physiology and a new approach to a selective immunosuppressive therapy by anti-IL-2-receptor monoclonal antibodies. Immunol. Rev 92:5-27.
4. Soulillou, J.P., D. Cantarovich., B. Le Mauff, M. Giral, N. Robillard, M. Hourmant, M. Hirn, and Y. Jacques. 1990. Randomized controlled trial of a monoclonal antibody against the interleukin 2- receptor (33B3 1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N. Engl J Med 322:1175-1182.
5. Lenschow, D.J., Y. Zeng, J.R. Thistlethweite, A. Montag, W. Brady, M.G Gibson, P.S. Linsle, and J.A. Bluestone. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig Science (Wash DC). 257: 789-792.
6. Turka, L.A., P.S. Linsley, and H. Lin. 1992. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. USA. 89:102-106.
7. Finck, B.K., P.S. Linsley, and D. Wofsy. 1994. Treatment of murine lupus with CTLA4Ig. Science (Wash. DC). 265:1225-1227.
8. Bogers, W.M.J.M, F. Lang, K.E. Parker, B. LeMauff, I. Anegon, Y. Jacques, and J.P. Soulillou. 1994. Rat interleukin-2 immunoglobulin M fusion proteins are cytotoxic in vitro for cells expressing the IL-2 receptor and can abolish cell-mediated immunity in vivo. Transplantation (Baltimore). 58:932-939.
9. Hock, H., M. Dorsch, U. Kunzendorf, Z. Qin, T. Diamantstein, and T. Blankenstein. 1993. Mechanisms of rejection induced by tumor cell targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon. Proc. Natl. Acad. Sci. USA 90:2774-2778.
10. Seed, B., and A. Aruffo. 1987. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc. Natl. Acad. Sci. USA. 84:3365-3369.
11. Aruffo, A., and B. Seed. 1987. Molecular cloning of two CD7 (T-cell leukemia antigen) cDNAs by a COS cell expression system. EMBO (Eur. Mol. Biol. Organ.) J. 6:3313-3316.
12. Osawa, H., and T. Diamantstein. 1984. A rat monoclonal antibody that binds specifically to mouse T lymphoblasts and inhibits IL 2 receptor functions: a putative anti-IL 2 receptor antibody. J. Immunol 132.2445-2450.
13. Diamantstein, T, W. Keppler, E. Blitstein-Willinger, and S. Ben-Efraim. 1976. Suppression of the primary immune response in vivo to sheep red blood cells by B-cell mitogens. Immunology 30:401-404.
14. Cordell, J.L., B. Falini, W.N. Erber, A.K. Gosh, Z. Abdulaziz, S. MacDonald, K.A F. Pulford, H. Stein, and D Y. Mason. 1984 Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatases and monoclonal anti-alkaline phosphatase (APAAP complexes). J. Histochem. Cytochem 32:219-229.
15. Linsley, P.S., P.M. Wallace, J. Johnson, M.G. Gibson, J.A. Greene, J.F. Ledbetter, C Singh, and M.A. Tepper. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule Science (Wash. DC). 257:792-795.
16. Dorf, M.E., M. Collis, M.J. Whitters, R.M. O'Hara, K. Kelleher, S. Jayaraman, and V.K. Kuchroo. 1989 Antigen specific suppressor cells, receptors, and factors. Prog. Immunol. 7:874-881.
17. Luo, Y , and M.E Dorf. 1993. Delayed-type hypersensitivity. In Current Protocols in Immunology. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober, editors. John Wiley & Sons, New York. 4.5.1-4.5.5.
18. Landolfi, N.F. 1991. A chimeric IL-2/Ig molecule possesses the functional activity of both proteins. J Immunol. 146:915-919.
19. Vie, H , T. Gouthier, R. Breathnach, M. Bonneville, A. Godard, J. Dietrich, G Karam, M.C. Gesnell, M.A. Peyrat, Y. Jacques, and J.P. Soulillou. 1992. Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA. 89:11337-11341
20. Byrn, R.A., J. Mordenti, C Lucas. D. Smith, S.A. Marsters, J.S. Johnson, P. Cossum, S.M Chamow, F.M. Wurm, T. Gregory, et al. 1990. Biological properties of a CD4 immunoadhesin. Nature (Lond.). 344:667-670.
21. Lenschow, D.J, Y. Zeng, J.R. Thistlethwaite, A Montag, W. Brady, M.G. Gibson, P.S. Linsley, and J.A. Bluestone. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science (Wash. DC) 257: 789-792.
22. Volk, H.D., S. Muller, S. Yarkoni, T. Diamantstein, and H Lorberboum-Galski. 1994. Mechanisms of dichotomous action of IL-2-pseudomonas exotoxin 40 (IL-2-PE40) on cell-mediated and humoral immune response. J. Immunol. 153:2497-2505.
23. Lenardo, M J. 1991. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature (Lond). 353:858-861
24. Baliga, P., K.D. Chavin, L Qin, J Woodward, J. Lin, P.S. Linsley, and J.S. Bromberg. 1994. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation (Baltimore). 58:1082-1090.
25. Dantal, J., Y. Jacquess, and J.P. Soulillou. 1991. Cluster-function relationship of rat-antimouse p55 IL-2 receptor monoclonal antibodies. Transplantation (Baltimore). 52.110-115.
26. Jonker, H., G. Goldstein, and H. Balner 1986. Effects of in vivo administration of monoclonal antibodies specific for human T cell subpopulations on the immune system in a rhesus monkey model. Transplantation (Baltimore). 35: 52-58
27. Ortega, R G , R.J. Robb, E.M. Shevach, and T.R. Malek. 1984. The murine IL-2 receptor. I. Monoclonal antibodies that define distinct functional epitopes on activated T cells and react with activated B cells. J. Immunol 133: 1970-1976.
28. Abrasion, D D., K.L. Hippen, M.A. Stacey, I. Mellman, G. Pani, K.A. Siminovitch, and J.C. Gambier. 1995. Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by FcRIIB1. Science (Wash. DC). 268:293-297.
29. Phillips, N.B., and D.C Parker. 1983. Fc-dependent inhibition of mouse B cell activation by whole anti-murine antibodies. J Immunol. 130:602-606.
30. Lane, P., T. Brocker, S. Hubele, E. Padovan, A. Lanzaveccia, and F. McConnell. 1993. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation. J. Exp. Med. 177: 1209-1213.
31. Che, S., and D.P. Huston. 1994. Natural killer cell suppression of IgM production. Nat Immun 13:258-269.